EBITDAM to bounce back at normalized level on the back of increased revenue traction and cost optimization (R&D;). largely led by lower base and volume up-tick on the back of increased domestic demand. In base, sales were impacted due to logistic issues and lack of regulatory guidelines/infrastructure on RT/PCR tests. Unlike strict lockdown restriction in last year, there are better recoveries and lesser logistic issues of global economies in 1QFY22....